Full-Ring Intracorneal Implantation in Corneas With Pellucid Marginal Degeneration

Sahar Mojaled Nobari,1 Consuelo Villena,1 and Khosrow Jadidi2,*

1 Department of Optics II (Optometry and Vision), Complutense University, Madrid, Spain
2 Department of Ophthalmology, Bina Eye Hospital Research Center, Tehran, IR Iran
*Corresponding Author: Khosrow Jadidi, Bina Eye Hospital Research Center, Tehran, IR Iran. Tel: +98-912053475, Fax: +98-212528042, E-mail: kh.jadidi@gmail.com

Received 2015 April 27; Revised 2015 July 29; Accepted 2015 October 19.

Abstract

Background: Keratoconus (KCN) is a progressive, non-inflammatory ectatic disorder characterized by bilateral and asymmetrical conical protrusion of the cornea. MyoRing implantation and Collagen Crosslink (CXL) are two separate effective treatments for all stages of keratoconus. This study aims to show the effect of these treatments combination in patients with moderate and severe keratoconus.

Objectives: The aim of this study was to report on the visual and refractive outcomes of corneas with pellucid marginal degeneration following MyoRing implantation (DIOPTEX GmbH).

Patients and Methods: This study included 15 eyes of 15 patients, with an age range from 22 to 49 years old, and pellucid marginal degeneration. An intrastromal corneal ring (MyoRing) was inserted by the means of mechanical dissection using a PocketMaker microkeratome. The main outcome measures were uncorrected distance visual acuity (UDVA), corrected distance visual acuity (CDVA), manifest refraction, and keratometry readings. The mean postoperative follow-up was ten months (range 6 - 12 months).

Results: The mean UDVA (LogMAR) improved significantly from 1.13 ± 0.21 preoperatively to 0.24 ± 0.13 postoperatively ($P < 0.001$), and the mean CDVA (LogMAR) improved significantly from 0.39 ± 0.12 to 0.09 ± 0.09 ($P < 0.001$). The mean cylinder of manifest refraction decreased significantly by 4.00 diopter (D) ($P < 0.001$). The mean spherical equivalent error (SE) decreased significantly from $-6.00 ± 3.60$ D to $-0.70 ± 1.90$ D, at the end of the follow-up period. Furthermore, with regards to corneal topography, a significant reduction was observed in keratometric values. The Kmax, Kmin and Kaverage decreased significantly by 5.00, 1.10 and 4.00 D, respectively ($P < 0.001$).

Conclusions: MyoRing implantation using the PocketMaker microkeratome appears to provide an effective method for treating pellucid marginal degeneration. Both UDVA and CDVA improved significantly. The corneal steepening and astigmatism were reduced in all subjects after MyoRing implantation.

Keywords: Pellucid Marginal Corneal Degeneration, Intrastromal Corneal Ring Implantation, MyoRing

1. Background

Pellucid marginal corneal degeneration (PMD) is a rare, non-inflammatory ectatic disorder of the inferior peripheral cornea characterized by a crescent-shaped band of inferior corneal thinning. The area of thinning is typically around 1 or 2 mm in width, which extends from 4 to 8-o’clock positions (1-4). The gold standard diagnostic test for PMD is corneal topography. The topographic appearance is a classical “butterfly” pattern demonstrating a large amount of against-the-rule astigmatism that makes the fitting of contact lenses difficult. Visual symptoms include long-standing poor visual acuity, which results from high irregular against-the-rule astigmatism (2-5).

The management of PMD depends on the severity of the disease. The non-surgical management of PMD includes spectacles and different groups of contact lenses (6-8), yet these procedures lose their effectiveness as the disease progresses. Patients with high or irregular astigmatism cannot be corrected with spectacles; in these cases, contact lens fitting is more difficult in pellucid eyes than keratoconic eyes as a result of central flattening and peripheral steepening (9-12).

In patients who cannot tolerate contact lenses or in those who do not achieve adequate visual acuity with contact lenses because of the degree of ectasia, several surgical procedures including penetrating keratoplasty, deep anterior lamellar keratoplasty, crescentic wedge resection, thermokeratoplasty, epikeratoplasty, and crescentic lamellar keratoplasty, have been proposed. However, all of these techniques are irreversible which require a long period of rehabilitation with unpredictable visual results (13-17). Due to the unsatisfactory results of the available treatments for PMD, the use of intracorneal ring segments (ICRS) has been proposed, in order to improve visual outcomes (18-24).

The MyoRing (Dioptex GmbH) is a 360° continuous intracorneal ring that is implanted into the cornea using the PocketMaker Microkeratome or femtosecond laser. The use of the MyoRing implantation has proven safe and
2. Objectives

The present study evaluated the visual and refractive outcomes as well as the patient satisfaction and ocular symptoms after MyoRing implantation in patients with pellucid marginal degeneration. To the best of our knowledge, this is the first study on MyoRing implantation for patients with pellucid marginal degeneration.

3. Patients and Methods

This retrospective study included 15 eyes of 15 patients, eleven males and four females, with a diagnosis of pellucid marginal degeneration (PMD) in whom MyoRing was implanted using thePocketMaker Microkeratome for PMD correction at Bina eye hospital, Tehran, Iran, between October 2012 and November 2013. All patients in this study had poor visual acuity with spectacles, contact lens intolerance or dissatisfaction, a clear central cornea, a minimum corneal thickness of 350 microns, and a mean keratometry between 45 and 52 D. The exclusion criteria were other ocular diseases, systemic conditions with a potential to cause refractive instability (pregnancy and diabetes), and previous ocular surgery on the implanted eye. All patients were informed about the operation as well as advantages and disadvantages of the procedure.

The diagnosis of PMD was made on the basis of slit lamp examination (inferior corneal thinning and ectasia above the area of maximum thinning), corneal topography (the "butterfly" or "kissing birds" pattern, steep contour in the peripheral inferior cornea with high keratometric powers radiating toward the center from the inferior oblique meridians) and refractive findings (significant against-the-rule astigmatism with CDVA loss). For all patients, preoperative and postoperative evaluations included uncorrected distance visual acuity (UDVA), corrected distance visual acuity (CDVA), manifest refraction, slit lamp biomicroscopy, dilated fundoscopy, Goldmann tonometry, corneal topography (Orbscan II, Baush and Lomb) and ultrasound pachymetry. Visual acuity was measured using the Snellen chart and transformed into a LogMAR value for statistical analysis.

Regarding visual symptoms and patient satisfaction, a subjective six-point Likert scale (0 = no, 1 = very low, 2 = low, 3 = moderate, 4 = high, 5 = very high) was used to measure overall satisfaction and visual symptoms, postoperatively.

3.1. Surgical Procedure

The procedures were performed by the same surgeon (KH.J) under sterile conditions and topical anesthesia (proparacaine hydrochloride 0.5%). An operation microscope (OMS-800 standard TOPCON corporation, Japan) was used to mark the central point of the intrastromal corneal ring. Additionally, the appropriate MyoRing dimensions were determined according to the MyoRing nomogram, which takes into account the corneal thickness at its thinnest point and the average keratometry (K)-reading.

An intrastromal pocket with 9 mm of diameter and 300 µm of depth was created via a small incision of 3 mm using the PocketMaker Microkeratome, as described in details elsewhere (25, 26). The Microkeratome has a suction ring and a motor-driven blade. First, the suction ring fixes the applicator to the cornea and then the micro-vibrating diamond creates the stromal pocket. Once the pocket is created, the MyoRing is inserted into the pocket using implantation forceps and centration is adjusted using a keratoscope. All procedures were performed with the temporal approach of self-sealing incisions. No intraoperative complications were noted during the surgical procedure in any of the cases. Postoperatively, a silicone bandage contact lens was placed on the cornea and removed 24 hours after the operation. Postoperative treatment included a combination of betamethasone drops (Sina Darou), chloramphenicol drops (Sina Darou), and non-preserved artificial tear (Artelac; Baush and Lomb), four times daily. Chloramphenicol was discontinued one week postoperatively whereas betamethasone was tapered during four to six weeks.

3.2. Statistical Analysis

Statistical analysis was performed using the SPSS version 16 for Windows (version 16; SPSS Inc. Chicago, IL, USA). All visual acuity measurements were converted from the Snellen notation to LogMAR. The normality of distribution was checked for all variables. Continuous variables are expressed as mean ± standard deviation (SD). Qualitative variables are reported as frequencies (percentages).

The differences between pre and postoperative refractive and visual outcomes were tested using the paired t-test. The results were compared between preoperative and postoperative examinations, with a mean follow-up of ten months. The threshold of statistical significance was a P value of less than 0.05.

4. Results

The study evaluated 15 eyes of 15 patients (73% males and 27% females) with a mean age of 29.7 ± 8 years (range 22 to 49 years). The mean duration of follow-up was 10 months (range 6 - 12 months). Table 1 summarizes preoperative and postoperative outcomes.

4.1. Visual Outcome

The mean UDVA (LogMAR) improved significantly from 1.13 ± 0.21, preoperatively, to 0.24 ± 0.12, postoperatively (P < 0.001). The UDVA improved in all eyes (100%). The improvement in mean UDVA was approximately nine lines of LogMAR. At the end of the follow-up period, 12 (80%) of the 15 eyes had a UDVA of 20/40 or more. The UDVA was 20/50 in three (20%) eyes, 20/40 in one (6%) eye, 20/32 in
nine (60%) eyes, and 20/20 in two (13%) eyes. The mean CDVA in LogMAR improved significantly from 0.40 ± 0.12 before the surgery to 0.18 ± 0.09 after the surgery (P < 0.001). The improvement in mean UDVA was two lines, postoperatively.

By the last visit of each patient, 73% of the eyes gained ≥ two lines of CDVA: two (13%) of 15 eyes gained five lines, three (20%) eyes gained three lines, six (40%) eyes gained two lines, and four (26%) eyes gained one line.

4.2. Refractive and Keratometry Outcomes

The mean decrease in spherical power, cylinder and spherical equivalent was 3.19, 4.00 and 5.00 D, respectively (P < 0.001).

The mean sphere of the manifest refraction decreased significantly from -3.20 ± 3.40, preoperatively to 0.01 ± 1.90, postoperatively (P < 0.001). The mean cylinder was -5.50 ± 1.20, preoperatively that reduced to -1.50 ± 1.00 at the end of the follow-up period (P < 0.001).

There was a significant reduction in the Spherical equivalent error (SE) from -6.00 ± 3.60, preoperatively to -0.70 ± 1.90, postoperatively at the end of the follow-up period (P < 0.001). Moreover, 10 of 15 eyes (66%) had a SE ranging from +1.00 to -1.00 D at the end of the follow-up period.

A significant reduction was observed in maximum, minimum, and average keratometry after MyoRing implantation. The amount of reduction was 5.00 D for the maximum keratometry reading (P < 0.001; Table 2).

4.3. Patient Satisfaction and Visual Symptoms

Based on the six-point Likert scale, mentioned in the methods section, all patients were satisfied with the MyoRing implantation. The level of satisfaction was very high in seven patients (46.7%), high in five patients (33.3%), moderate in two patients, and low in one patient.

Regarding the visual symptoms, we asked the patients about the most common symptoms following ICRS implantation including glare, halo, night vision, fluctuation and activity limitation. The majority of the patients had no severe symptoms. Nine patients (60%) declared no fluctuation in their vision, postoperatively, while four patients (26%) had very low and two (13%) had low fluctuation.

Halo, glare, and night vision were high in one (6%) patient. With respect to the activity limitation, 12 patients (80%) had no activity limitation after MyoRing implantation. Table 3 demonstrates the score of the visual symptoms and the overall satisfaction, postoperatively.

### Table 1. Visual and Refractive Outcomes

| Parameter       | Preoperative | Postoperative | P Value  |
|-----------------|--------------|---------------|----------|
| UDVA (log MAR)  | 1.13 ± 0.21  | 0.24 ± 0.12   | < 0.001  |
| CDVA (log MAR)  | 0.4 ± 0.12   | 0.18 ± 0.09   | < 0.001  |
| Sphere (D)      | -3.20 ± 3.40 | 0.01 ± 1.90   | < 0.001  |
| Cylinder (D)    | -5.50 ± 1.20 | -1.50 ± 1.00  | < 0.001  |
| SE (D)          | -6.00 ± 3.60 | -0.70 ± 1.90  | < 0.001  |

a Abbreviations: D, diopters; CDVA, corrected distance visual acuity; SE, spherical equivalent; UDVA, uncorrected distance visual acuity.

### Table 2. Mean of the Keratometric (K) Values Preoperatively and Postoperatively and the Amount of Reduction

| K-Values       | Preoperative | Postoperative | Pre-Post | P Value  |
|----------------|--------------|---------------|----------|----------|
| Kmax (D)       | 51.1 ± 2.40  | 46.1 ± 2.00   | 5.00 D   | < 0.001  |
| Kmin (D)       | 44.8 ± 2.00  | 43.7 ± 2.30   | 1.10 D   | < 0.001  |
| Kaverage (D)   | 48.0 ± 2.20  | 44.0 ± 2.60   | 4.00 D   | < 0.001  |

a Abbreviations: D, Diopters; Kmax, maximum K value in diopters; Kmin, minimum K value in diopters; Kmean, average K value in diopters.

b Difference between preop and postop K.

### Table 3. Postoperative Visual Symptoms and Patient Satisfaction Score

| Parameters      | No    | Very Low | Low    | Moderate | High   | Very High |
|-----------------|-------|----------|--------|----------|--------|-----------|
| Halo            | 5 (33.3) | 5 (33.3) | 2 (13.3) | 2 (13.3) | 1 (6.7) | 0         |
| Glare           | 5 (33.3) | 3 (20)   | 5 (33.3) | 1 (6.7)  | 1 (6.7) | 0         |
| Night vision    | 6 (40)  | 2 (13.3) | 3 (20)  | 3 (20)   | 1 (6.7) | 0         |
| Fluctuation     | 9 (66.6)| 4 (26.7) | 2 (6.7) | 0        | 0      | 0         |
| Activity limitation | 12 (80)   | 2 (13.3) | 1 (6.7) | 0        | 0      | 0         |
| Overall satisfaction | 0   | 0        | 2 (13.3) | 1 (6.7)  | 5 (33.3) | 7 (46.7) |

a Data are presented as No. (%).
5. Discussion

Appropriate and effective treatment of PMD is a challenge in ophthalmology. The management of PMD depends on the severity of the disease. The ICRS are semicircular mechanical devices that have been successfully used in PMD to delay penetrating keratoplasty, improve contact lens intolerance, and visual results. Various studies have shown that ICRS implantation is a safe and irreversible method for the management of pellucid marginal degeneration (18-24).

The MyoRing is a full-ring intracorneal implant that reduces corneal irregularity in keratoconic eyes as a result of the flattening effect (27-32). This corneal flattening could be useful in pellucid corneas for minimizing corneal protrusion and consequently the refractive error. Relative centration and minimization of the peripheral corneal protrusion have been observed after ICRS implantation in corneas with PMD (18-20).

It has been demonstrated that the treatment of keratoconus and post-LASIK ectasia with MyoRing implantation is effective, minimally invasive and easy to perform (27-32). This research studied the eyes of 15 patients with PMD who had MyoRing implantation. Moreover, the study concentrated on two major areas. Firstly, visual and refractive outcomes were assessed. Secondly, patients’ satisfaction was acquired post-operatively along with their ocular symptoms. To the best of our knowledge, there has been a lack of academic publications in association with MyoRing implantation using Pocketmaker Microkeratome on patients with PMD, and the uniqueness of this study regarding content and the considerable differences in the findings have made this unprecedented work more valuable. The outcomes of our study showed that MyoRing implantation in PMD was efficient in flattening the cornea and thereby improving UDVA and CDVA in the patients. The maximum k-value decreased by 5.00 D. The improvement in the mean UDVA after MyoRing implantation was approximately nine lines. Furthermore, the mean CDVA gain was two lines. A significant reduction (5.30 D) was observed in the spherical equivalent error (SE), postoperatively. These outcomes were consistent with changes reported in previous studies on ICRS implantation in pellucid corneas (19-24). However, we observed a greater reduction in spherical equivalent error and keratometric values when compared with other studies.

Mularoni et al. (22) reported a reduction of 3.40 D in SE of eight eyes with PMD implanted by Intacs. In a study by Kubaloglu et al. (24) the mean reduction in SE was approximately 2.50 D after 210° arc length KeraRing implantation in 16 eyes with PMD. Pinero et al. (23) carried out KeraRing and Intacs insertion for 21 pellucid corneas and reported that SE was reduced by 2.75 D, after six months of follow-up.

In our study, a statistically significant reduction (4.00 D) was observed in the manifest cylinder, postoperative-
ening effect of the incision and the effect of the ring. On the other hand, there is no study suggesting that the location of the incision has an effect on the final outcome and therefore additional comparative studies are required to compare the outcomes between flat and steep incisions.

In terms of postoperative clinical complications, we did not observe any serious complications including decentration, extrusion, explantation, keratitis, or vascularization. It has been shown that MyoRing implantation is a safe technique with a low incidence of complications to correct keratoconus and post LASIK ectasia (28-32).

Although diurnal changes in the visual acuity as well as visual symptoms are well-known phenomena after ICRS insertion (33, 34), they were not a significant cause of patient dissatisfaction in our study. The majority of the patients were satisfied with MyoRing implantation; 47% of the patients were very highly satisfied at the end of the follow-up. Only one patient had low satisfaction at six months follow-up because of severe glare and night vision problems. In order to minimize these symptoms, pilocarpine 1% eye drops were prescribed.

The most frequent postoperative complication after ICRS implantation is extrusion, which leads to the explantation of the ring. Explantation may be performed if the patient is dissatisfied with the visual outcomes. The food and drug administration (FDA) and European studies have reported ICRS dissatisfaction due to vision or unbearable visual symptoms in up to 8% of eyes (35, 36). Since MyoRing is a continuous full ring with no free ends, no extrusion was observed as a postoperative complication, following MyoRing implantation.

In the present study, no patient lost lines of acuity as a result of serious complications; two patients had little and four patients had very little fluctuating vision. The fluctuation in vision was likely the result of an unstable tear film after MyoRing implantation. For these cases, we recommended the use of viscous artificial tear.

Despite the limited number of patients in this study, MyoRing implantation using the PocketMaker was a safe and effective procedure that reduced corneal steepening and refractive error in patients with PMD. MyoRing implantation significantly improved UDVA and CDVA, although the increase in UDVA was more impressive.

Following MyoRing implantation in the current study, more significant reduction was obtained in keratometric values and spherical equivalent error, compared to Intacs and KeraRing. Therefore, it could be concluded that MyoRing implantation in patients with PMD appears to have a greater effect on corneal power. We believe that this new technique with unique and specialized characteristics of MyoRing implantation by means of PocketMaker Microkeratome could explain the reliability of the results of this study. Considering the fact that PMD is an ecstatic disorder, it remains uncertain whether MyoRing can control the progression of the disease.

In spite of the good visual and refractive outcomes following MyoRing implantation in pellucid corneas, further randomized prospective studies with longer follow-up periods are required to evaluate the stability of the MyoRing and its impact on disease progression.

Acknowledgments

We would like to acknowledge Sara Serahati for her contribution to the statistical analysis.

Footnote

Authors’ Contribution: Sahar Mojaled Nobari participated in study design and wrote draft of the manuscript. Consuelo Villena conceived of the study and revised the manuscript. Khosrow Jadidi conceived the study and carried out the statistical analysis. All authors read and approved the final manuscript.

References

1. Srividh MS, Mahesh S, Bansal AK, Nutheti R, Rao GN. Pellucid marginal corneal degeneration. Ophthalmology. 2004;111(5):1026-7. doi:10.1016/j.ophtha.2003.09.035. [PubMed: 15177959]
2. Krachmer JH, Feder RS, Belin MW. Keratoconus and related noninflammatory corneal thinning disorders. Surv Ophthalmol. 1984;28(4):299-322. doi: 10.1016/S0039-6257(84)90108-5. [PubMed: 6327457]
3. Krachmer JH. Pellucid marginal corneal degeneration. Arch Ophthalmol. 1978;96(7):1217-21. [PubMed: 3528310]
4. Robin JB, Schanzlin DJ, Verity SM, Barron BA, Arffa RC, Suarez I, et al. Peripheral corneal disorders. Surv Ophthalmol. 1988;31(1):1-36. [PubMed: 3592467]
5. Karabatsas CH, Cook SD. Topographic analysis in pellucid marginal corneal degeneration and keratoglobus. Eye (Lond). 1996;10(4):459-465. doi: 10.1038/eye.1996.59. [PubMed: 9844096]
6. Liu J, Leach NE, Bergmann JP. Reverse-geometry gas-permeable lens design for pellucid marginal degeneration. Eye Contact Lenses. 2005;31(3):127-9. doi: 10.1097/ICL.0b013e3181939abf. [PubMed: 15894880]
7. Kompella VB, Aasuri MK, Rao GN. Management of pellucid marginal corneal degeneration with rigid gas permeable contact lenses. CLAO J. 2002;28(3):140-5. doi: 10.1207/S15324452CLAOJ2803_3.
8. Raizada K, Srividh MS. Nomogram for spherical RGP contact lens fitting in patients with pellucid marginal corneal degeneration (PMCD). Eye Contact Lens. 2003;29(3):568-72. doi: 10.1097/01. ICL.0b013e31815c859b. [PubMed: 12885811]
9. Mahadevan R, Anumula A, Valarmathi A. Retrospective study of contact lens fitting in pellucid marginal degeneration. Eye Contact Lenses. 2008;34(4):207-10. doi: 10.1097/ICL.0b013e3181865f29. [PubMed: 18784272]
10. Artin CI. The long-term use of the SoftPerm lens on pellucid marginal corneal degeneration. Clao J. 1994;20(4):258-60. doi: 10.1207/s15324452claoj2004_2. [PubMed: 8780923]
11. Nau AC. A comparison of synergesys versus traditional rigid gas permeable lenses designs for patients with irregular corneas. Eye Contact Lens. 2008;34(4):295-299. doi: 10.1097/ICL.0b013e31815c859b. [PubMed: 18784245]
12. Trelkiss PF, Cohen EJ, Rapuano CJ, Hammersmith KM, Laibson PR. Management of pellucid marginal corneal degeneration. Cornea. 2005;24(5):555-60. [PubMed: 15968160]
13. Cameron JA. Results of lamellar crescentic resection for pellucid marginal corneal degeneration. Am J Ophthalmol. 1992;113(3):296-302. doi: 10.1016/S0002-9394(16)32605-1. [PubMed: 1543223]
14. Varley GA, Macsai MS, Krachmer JH. The results of penetrating keratoplasty for pellucid marginal corneal degeneration. Am J Ophthalmol. 1990;110(2):230-5. doi: 10.1016/0002-9394(90)90119-0. [PubMed: 23781797]
15. Javadi MA, Karimian F, Hosseinzadeh A, Noroozizadeh HM, Sa’eedifar MR, Rabie HM. Lamellar crescentic resection for pellucid marginal corneal degeneration. Refract Surg. 2004;20(2):362-5. doi: 10.1016/j.rbm.2004.07.050. [PubMed: 15072316]
16. MacLean H, Robinson LP, Wechsler AW. Long-term results of cor-
Al-Torbak AA. Deep anterior lamellar keratoplasty for pellucid marginal degeneration. Saudi J Ophthalmol. 2013;27(1):1-4. doi: 10.1016/j.sjopt.2012.04.001. [PubMed: 23164380]

Kymionis GD, Aslanides IM, Siganos CS, Pallikaris IG. Intacs for early pellucid marginal degeneration. J Cataract Refract Surg. 2004;30(1):230-3. doi: 10.1016/S0886-3550(03)00656-4. [PubMed: 14967293]

Akaishi L, Tzelakis PF, Raber IM. Ferrara intracorneal ring implantation and cataract surgery for the correction of pellucid marginal corneal degeneration. J Cataract Refract Surg. 2004;30(1):2427-30. doi: 10.1016/j.jcrs.2004.04.047. [PubMed: 15591010]

Rodriguez-Prats J, Galal A, Garcia-Lledo M, De La Hoz F, Alio JL. Intracorneal rings for the correction of pellucid marginal degeneration. J Cataract Refract Surg. 2003;29(7):1421-4. [PubMed: 12900254]

Ertan A, Bahadir M. Intrastromal ring segment insertion using a femtosecond laser to correct pellucid marginal corneal degeneration. J Cataract Refract Surg. 2006;32(10):2710-6. doi: 10.1016/j.jcrs.2006.06.015. [PubMed: 17010872]

Mularoni A, Torreggiani A, di Biase A, Laffi GL, Tassinari G. Conservation and cataract surgery for the correction of pellucid marginal degeneration. J Cataract Refract Surg. 2005;31(4):660-6. doi: 10.1016/j.jcrs.2004.10.050. [PubMed: 15808259]

Pinero DP, Alio JL, Morbelli H, Uceda-Montanes A, El Rady B, Coskunseven E, et al. Refractive and corneal aberrometric changes after intracorneal ring implantation in corneas with pellucid marginal degeneration. Ophthalmology. 2009;116(9):1656-64. doi: 10.1016/j.ophtha.2009.06.002. [PubMed: 19643482]

Kubalougli A, Sari ES, Cinar Y, Koyrak A, Kurnaz E, Pinero DP, et al. A single 210-degree arc length intrastromal corneal ring implantation for the management of pellucid marginal corneal degeneration. Am J Ophthalmol. 2010;150(2):185-92 e1. doi: 10.1016/j.ajo.2010.03.020. [PubMed: 20570241]

Daxer A. Corneal intrastromal implantation surgery for the treatment of moderate and high myopia. J Cataract Refract Surg. 2008;34(2):294-8. doi: 10.1016/j.jcrs.2007.10.011. [PubMed: 18242439]

Daxer A. Adjustable intracorneal ring in a lamellar pocket for keratoconus. J Refract Surg. 2010;26(5):217-21. doi: 10.3928/1081597X-20100224-08. [PubMed: 20229955]

Daxer A. MyoRing for central and noncentral keratoconus. J Refract Surg. 2012;28:117-9.

Daxer A, Mahmoud H, Venkateswaran RS. Intracorneal continuous ring implantation for keratoconus: One-year follow-up. J Cataract Refract Surg. 2010;36(8):1296-302. doi: 10.1016/j.jcrs.2010.03.039. [PubMed: 20656151]

Alio JL, Pinero DP, Daxer A. Clinical outcomes after complete ring implantation in corneal ectasia using the femtosecond technology: A pilot study. Ophthalmology. 2014;121(7):1382-90. doi: 10.1016/j.ophtha.2014.02.012. [PubMed: 24649460]

Jabbarvand M, Salamatrad A, Hashemian H, Khodaparast M. Continuous corneal intrastromal ring implantation for treatment of keratoconus in an Iranian population. Am J Ophthalmol. 2013;155(5):837-42. doi: 10.1016/j.ajo.2012.11.015. [PubMed: 23336932]

Jabbarvand M, Salamatrad A, Hashemian H, Mazloumi M, Khodaparast M. Continuous intracorneal ring implantation for keratoconus using a femtosecond laser. J Cataract Refract Surg. 2014;40(2):1710-6. doi: 10.1016/j.jcrs.2014.01.014. [PubMed: 25069311]

Mojaled-Nobari S, Villena C, Jadidi K. Predictability, Stability and Safety of MyoRing Implantation in Keratocoric Eyes During One Year Follow-Up. Iran J Ophthalmol. 2014;26(3):136-43.

Ruckhofer J, Stoiber J, Alzner E, Grabner G. One year results of European Multicenter Study of intrastromal corneal ring segments. Part 2: complications, visual symptoms, and patient satisfaction. J Cataract Refract Surg. 2001;27(2):287-96. [PubMed: 11287979]

Baikoff G, Maia N, Poulhalac D, Fontaine A, Gusiano B. Diurnal variations in keratometry and refraction with intracorneal ring segments. J Cataract Refract Surg. 1999;25(9):1036-61. doi: 10.1016/S0886-3550(99)00352-2. [PubMed: 10445909]

Schanzlin DJ, Abbott RL, Asbell PA, Assil KK, Burris TE, Durrie DS, et al. Two-year outcomes of intracorneal ring segments for the correction of myopia. Ophthalmology. 2001;108(9):1688-94. [PubMed: 11535474]

Schanzlin DJ. Studies of intrastromal corneal ring segments for the correction of low to moderate myopic refractive errors. Trans Am Ophthalmol Soc. 1999;97:385-90. [PubMed: 10703446]

Mojaled Nobari S et al.